About
Dr. Elara Singh designs and oversees clinical trials for novel peptide therapeutics at Harvard Medical School. Her adaptive trial designs have accelerated three peptide drugs through Phase II evaluation.
Summary
Architect of the adaptive dose-escalation framework now used in over 20 ongoing peptide clinical trials globally.
Key Lessons
A flawed comparator arm in an early trial taught her that peptide-placebo blinding requires specialized formulation expertise to truly mask injection-site reactions.
Certifications
- M.D./Ph.D., Harvard
- ACRP Certified Principal Investigator
- FDA Clinical Advisory Committee
Areas of Expertise
- Peptide trial endpoints
- Dose-escalation protocols
- Regulatory strategy